William B. Horne

CEO William B. Horne purchases 200,000 shares at $0.17; stock now at $0.15, down 96.9% from $4.88 high. Company unprofitable with $-30.0M net income.

CEO William B. Horne purchased 200,000 shares at $0.17 on 2026-06-11, establishing an initial stake in Hyperscale Data, Inc. The stock has declined to $0.15 since purchase and sits near its 52-week low, down 96.9% from a $4.88 peak, suggesting a severely distressed valuation. However, the company's fundamentals are concerning: the most recent quarter showed $44.1M in revenue against a $-30.0M net loss, and annual revenue contracted 4.3% year-over-year with the company remaining unprofitable over its most recent full fiscal year. Horne's cross-ticker track record shows strong prior returns (avg 30d return +519.6%, 100% win rate across 3 buys), but that historical performance is disconnected from this specific ticker and does not address the current operational losses or revenue decline at GPUS. The divergence between the executive's purchase and the company's financial deterioration warrants examination of whether this represents conviction in a turnaround strategy or other considerations beyond disclosed fundamentals.

ALZN Director Horne buys 3.3K shares at $0.99; stock down 89.7% from 52-week high; unprofitable company; cluster pattern with 2 other insiders buying within 14 days.

Director William B. Horne purchased 3,334 shares at $0.99 on 2025-03-26, increasing his holdings to 30,000 shares and representing a +12.5% increase in his position. The stock is currently trading at $9.90, down 89.7% from its 52-week high of $96.30, suggesting a dramatic valuation reset. Fundamentals are weak: Alzamend Neuro reported negative net income of $-1,039,434.00 over its most recent full fiscal year, and the company is unprofitable. However, the timing and clustering are notable—this is the director's third consecutive buy at ALZN within 6 days (prior buys on 2025-03-20 and 2025-03-18), and 2 other insiders also bought within the past 14 days, creating a cluster buy pattern. This repeated accumulation by multiple insiders at deeply depressed prices, despite negative fundamentals, merits close examination of whether management has information about stabilization, recapitalization, or strategic developments not yet disclosed to the market.

Director William B. Horne purchased 5,000 ALZN shares at $0.98 on March 20, 2025; holdings now 26.7K shares.

Director William B. Horne purchased 5,000 shares at $0.98, increasing his holdings by 23.1% to 26.7K shares. The transaction occurred while Alzamend Neuro trades at $8.80, down 90.9% from a 52-week high of $96.30 and off 9.5% over 30 days, indicating a company in significant distress. Fundamentally, the company posted a negative net income of $-1.0M in its most recent fiscal year, with a modest market cap of $58.1M, signaling ongoing unprofitability. This purchase represents only the director's second open-market buy across his entire cross-ticker history and his second transaction at ALZN within two trading days (following a March 18 purchase), but offers limited insight into conviction given the extremely small sample size and absence of prior measurable outcomes at this ticker.

Director William B. Horne buys 5,000 ALZN shares at $0.97, raising stake to 21,666 shares amid -91.1% tumble from 52-week high.

Director Horne purchased 5,000 shares at $0.97 on 2025-03-18, increasing his holdings by 30.0% from 16,666 to 21,666 shares. The transaction occurred as the stock trades at $8.56, down 91.1% from its 52-week high of $96.30, and has declined 23.9% over the past 90 days. The company reported negative net income of $-1,039,434.00 for its most recent full fiscal year. The combination of a substantial accumulated losses, pronounced price decline from peak, and a director's purchase at depressed prices relative to recent history warrants examination of whether this represents opportunistic accumulation or reflects underlying confidence in operational recovery.